Kura Oncology (NASDAQ:KURA) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Kura Oncology (NASDAQ:KURA) from a strong sell rating to a hold rating in a research report released on Saturday morning.

Other research analysts also recently issued reports about the stock. UBS Group reissued a “buy” rating and set a $15.00 price objective (down from $16.00) on shares of Kura Oncology in a research report on Friday, March 13th. Zacks Research raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 26th. Wedbush reduced their target price on shares of Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, March 6th. Lake Street Capital assumed coverage on shares of Kura Oncology in a research note on Tuesday, April 14th. They issued a “buy” rating and a $23.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research note on Tuesday, April 21st. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $26.38.

Kura Oncology Trading Down 5.3%

NASDAQ KURA opened at $9.22 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.05. The firm’s fifty day moving average price is $8.90 and its 200 day moving average price is $9.47. The company has a market capitalization of $818.46 million, a price-to-earnings ratio of -2.75 and a beta of 0.32. Kura Oncology has a 12 month low of $5.45 and a 12 month high of $12.49.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. The firm had revenue of $18.27 million for the quarter, compared to the consensus estimate of $25.97 million. On average, sell-side analysts expect that Kura Oncology will post -3.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

Hedge funds have recently added to or reduced their stakes in the business. Sector Gamma AS purchased a new position in Kura Oncology during the 3rd quarter valued at about $3,880,000. Nan Fung Trinity HK Ltd. purchased a new position in Kura Oncology during the 3rd quarter valued at about $2,043,000. SG Americas Securities LLC grew its holdings in shares of Kura Oncology by 214.1% during the fourth quarter. SG Americas Securities LLC now owns 151,715 shares of the company’s stock worth $1,576,000 after buying an additional 103,411 shares in the last quarter. Rhenman & Partners Asset Management AB raised its position in shares of Kura Oncology by 96.0% in the third quarter. Rhenman & Partners Asset Management AB now owns 490,000 shares of the company’s stock valued at $4,336,000 after buying an additional 240,000 shares during the last quarter. Finally, Moody Aldrich Partners LLC acquired a new position in shares of Kura Oncology in the fourth quarter valued at approximately $1,867,000.

More Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: Kura emphasized a strong start for KOMZIFTI, noting about $5.8 million in first full launch-quarter sales, which suggests early commercial traction. Kura targets 2028 first top line KOMET-017 Phase III results as KOMZIFTI posts $5.8M in first full launch quarter
• Positive Sentiment: Brokerage commentary remained constructive overall, with Barclays reportedly reiterating a Buy and analysts collectively maintaining a Moderate Buy view. Kura Oncology (KURA) Receives a Buy from Barclays
• Neutral Sentiment: In its Q1 earnings discussion, Kura highlighted the commercial launch of KOMZIFTI and pipeline milestones, including plans for KOMET-017 Phase III topline results in 2028. Kura Oncology Inc (KURA) Q1 2026 Earnings Call Highlights: Strong KOMZIFTI Launch Amid Rising …
• Negative Sentiment: HC Wainwright lowered earnings estimates across several periods, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, FY2028, and FY2029, signaling expectations for deeper losses than previously modeled.
• Negative Sentiment: The most recent revisions were especially notable for FY2026 and FY2027, where projected EPS losses widened, reinforcing concerns that profitability remains distant.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.